Tuesday, TG Therapeutics, Inc. (TGTX) announced positive topline Phase 1 data for BRIUMVI in patients with myasthenia gravis, a chronic autoimmune neuromuscular disease. At Week 24, 82 per cent of patients who received BRIUMVI achieved the Minimal Clinically Important Difference in MG-ADL, with a...
Monday, Tango Therapeutics, Inc. (TNGX) announced positive initial data from its ongoing Phase 1/2 study of vopimetostat in combination with Revolution Medicines' RAS(ON) inhibitors daraxonrasib or zoldonrasib. During the study, patients with MTAP-deleted and RAS-mutant metastatic pancreatic ductal...
Fractyl Health, Inc. (GUTS), a clinical-stage metabolic therapeutics company, on Thursday announced positive one-year results for Revita from its REVEAL-1 Cohort study. Revita is the company's lead product candidate, designed to remodel the duodenal lining of the small intestine through a one-time,...
argenx SE (ARGX), an immunology company, on Wednesday reported positive data for efgartigimod in autoimmune rheumatic diseases, including myositis and Sjogren's disease, ahead of presentations at the EULAR 2026 Congress in London. In the ongoing ALKIVIA+ extension study in myositis, patients who continued...
Gilead Sciences, Inc. (GILD) announced Tuesday positive results from a Phase 3 study in people with primary biliary cholangitis (PBC), showing that treatment with Livdelzi (seladelpar) led to significantly more patients achieving normalization of alkaline phosphatase (ALP). ALP is a key liver marker...
AstraZeneca PLC (AZN) on Monday reported positive results from the Phase III EMERALD-3 trial, showing that its IMFINZI (durvalumab)-based combination therapy significantly improved progression-free survival in patients with unresectable hepatocellular carcinoma (HCC) eligible for embolization. The...
Jade Biosciences, Inc. (JBIO), a clinical-stage biotechnology company, on Monday reported positive interim results from a Phase 1 trial evaluating JADE101 for the treatment of immunoglobulin A nephropathy (IgAN). The company's shares were up more than 10% in pre-market trading.
Dizal (688192.SS) announced the results from the phase 3 WU-KONG28 study showing that ZEGFROVY monotherapy demonstrated superior anti-tumor efficacy, compared to platinum-doublet chemotherapy, in untreated NSCLC patients with EGFR exon 20 insertion mutations. Xiaolin Zhang, CEO of Dizal, said: "WU-KONG28...
Johnson & Johnson (JNJ) on Friday reported new positive results from the Phase 3 MajesTEC-9 study evaluating TECVAYLI in patients with relapsed or refractory multiple myeloma treated as early as second line. The study showed that treatment with TECVAYLI reduced the risk of disease progression or death...
Pfizer Inc. (PFE) on Friday reported seven-year follow-up results from the Phase 3 CROWN trial showing that LORBRENA significantly improved progression-free survival compared with XALKORI in patients with previously untreated ALK-positive advanced or metastatic non-small cell lung cancer. At seven...
Friday, Agios Pharmaceuticals, Inc. (AGIO) announced its decision to discontinue the study of tebapivat, a next-generation oral pyruvate kinase activator designed to provide optimized clinical benefits for patients with rare hematologic diseases. The decision comes as results from its Phase 2b trial...
TG Therapeutics, Inc. (TGTX) on Wednesday reported positive topline results from its Phase 3 ENHANCE study evaluating a single-infusion initiation regimen for BRIUMVI in adults with relapsing forms of multiple sclerosis. The study achieved its primary endpoint, showing bioequivalent drug exposure...
Apogee Therapeutics, Inc. (APGE), a clinical-stage biotechnology company, announced Wednesday positive 16-week data from Part B of the Phase 2 APEX clinical trial of zumilokibart (APG777), a potential best-in-class anti-IL-13 antibody, in patients with moderate-to-severe AD. The trial met all its...
Hansa Biopharma AB (HNSA.ST) on Wednesday announced positive topline results from the European post-authorization efficacy study of Idefirix in kidney transplant patients. The study evaluated one-year graft failure-free survival and patient survival in highly sensitized patients who underwent HLA-incompatible...
Shanghai Junshi Biosciences Co., Ltd. (1877.HK) on Wednesday said its phase III study of toripalimab combined with platinum-containing doublet chemotherapy as perioperative treatment for resectable stage II-III non-small cell lung cancer met the primary endpoint. The primary endpoints were event-free...
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.